熱門資訊> 正文
阿尔托神经科学精神分裂症治疗显示良好的1期结果
2024-04-24 01:21
- ALTO-101, a novel PDE4 inhibitor under investigation from Alto Neuroscience (NYSE:ANRO) for cognitive impairment associated with schizophrenia ("CIAS"), demonstrated positive phase 1 results in healthy subjects.
- The candidate, which Alto licensed from Sanofi (SNY), is administered as a transdermal patch through a partnership with MEDRx.
- The study was designed to compare tolerability and pharmacokinetics of ALTO-101 when administered via a transdermal patch compared to a pill.
- Results showed favorable tolerability and improved pharmacokinetics of the patch compared to oral administration.
- "The drug exposure levels achieved with the transdermal formulation were significantly greater than systemic exposure with oral administration while also reducing typical class-wide adverse events.," Alto (ANRO) said in a news release.
- In H1 2024, the company plans a proof-of-concept study evaluating ALTO-101 in patients with CIAS. Top-line date is projected in H2 2025.
- Alto (ANRO) is up ~3% in early Tuesday afternoon trading.
More on Alto Neuroscience
- Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders
- Stifel, Baird, Jefferies bullish on Alto Neuroscience, cite upcoming data
- Alto Neuroscience stock rallies 35% following upsized IPO
- Historical earnings data for Alto Neuroscience
- Financial information for Alto Neuroscience
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
